Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthRX vs OlleveCare

HealthRX
Graded #8

Higher grade

vs+39.89999999999999
OlleveCare
Graded #497

Lower grade

The verdict

HealthRX takes it — 86.1/100 to 46.2/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +40
85
45
Dose & formulationHealthRX +50
90
40
Clinical oversightHealthRX +34
87
53
Labs & monitoringHealthRX +33
82
49
FulfillmentHealthRX +48
86
38
Contract termsHealthRX +30
85
55
HealthRX · left barOlleveCare · right bar

The numbers

MetricHealthRXOlleveCare
WeighScore86.1/10046.2/100
GradeBC
Scorecard rank#8#497
Semaglutide$189/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageNot publicly listed13 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard